Final answer:
A Part D sponsor must establish an MTM program under 42 CFR §423.153(d) that enhances therapeutic outcomes for patients by optimizing medication use and reducing adverse drug events.
Step-by-step explanation:
Under 42 CFR §423.153(d), Part D sponsors are mandated to institute a Medication Therapy Management (MTM) program aimed at enhancing therapeutic outcomes for specific beneficiaries. The program's objective is to improve medication utilization and mitigate the risk of adverse drug events. Ensuring optimal use of covered Part D drugs is a key goal, contributing to favorable therapeutic outcomes and minimizing the potential for adverse drug interactions. The comprehensive MTM program encompasses various services, including medication therapy reviews, pharmacotherapy consults, anticoagulation management, immunizations, and other clinical services.
By providing these services, Part D sponsors aim to optimize medication regimens, promote patient well-being, and reduce the likelihood of negative drug-related incidents, aligning with broader healthcare goals of quality and safety in pharmaceutical management.